Latest Period
Q4 2025
Security Snapshot
Atara Biotherapeutics, Inc. - Common Stock (ATRA) Institutional Ownership
CUSIP: 046513206
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
40
Shares (Excl. Options)
2,049,655
Price
$18.09
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- ATRA on Nasdaq
- Shares outstanding
- 7,230,838
- Price per share
- $4.89
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 2,049,655
- Total reported value
- $37,062,796
- % of total 13F portfolios
- 0%
- Share change
- +166,547
- Value change
- +$3,113,209
- Number of holders
- 40
- Price from insider filings
- $4.89
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ATRA - Atara Biotherapeutics, Inc. - Common Stock is tracked under CUSIP 046513206.
- 40 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 40 to 7 between Q4 2025 and Q1 2026.
- Reported value moved from $37,062,796 to $1,677,293.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 40 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 046513206?
CUSIP 046513206 identifies ATRA - Atara Biotherapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 046513206:
Significant Owners of Atara Biotherapeutics, Inc. - Common Stock (ATRA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 9.9% | 0% | $10,764,875 | +$659,400 | 751,223 | +6.5% | Redmile Group, LLC | 12 Nov 2025 |
| EcoR1 Capital, LLC | 9.9% | $10,258,030 | 715,853 | EcoR1 Capital, LLC | 30 Sep 2025 | |||
| Panacea Innovation Ltd | 9.5% | $4,180,000 | 550,000 | Panacea Venture Healthcare Fund II, L.P. | 30 Jan 2025 |
As of 31 Dec 2025, 40 institutional investors reported holding 2,049,655 shares of Atara Biotherapeutics, Inc. - Common Stock (ATRA). This represents 28% of the company’s total 7,230,838 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) together control 28% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 7.9% | 573,183 | 0% | 0.48% | $10,368,880 |
| Redmile Group, LLC | 6.1% | 441,701 | 0% | 0.59% | $7,990,371 |
| VANGUARD GROUP INC | 3.1% | 225,940 | +11% | 0% | $4,087,255 |
| MARSHALL WACE, LLP | 2.1% | 148,632 | +28% | 0% | $2,688,752 |
| GLOBEFLEX CAPITAL L P | 1.1% | 77,224 | +400% | 0.21% | $1,396,982 |
| BlackRock, Inc. | 0.93% | 67,108 | -3.9% | 0% | $1,213,984 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.86% | 62,381 | +3.1% | 0% | $1,129,112 |
| MACKENZIE FINANCIAL CORP | 0.81% | 58,668 | -8.1% | 0% | $1,046,920 |
| ACADIAN ASSET MANAGEMENT LLC | 0.75% | 54,048 | -4.2% | 0% | $976,000 |
| STALEY CAPITAL ADVISERS INC | 0.69% | 50,000 | 0% | 0.04% | $904,500 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.45% | 32,691 | +134% | 0.01% | $591,380 |
| RENAISSANCE TECHNOLOGIES LLC | 0.42% | 30,040 | +59% | 0% | $543,424 |
| STATE STREET CORP | 0.37% | 26,453 | +4.8% | 0% | $478,535 |
| Cambridge Investment Research Advisors, Inc. | 0.32% | 22,864 | +34% | 0% | $414,000 |
| Quadrature Capital Ltd | 0.28% | 20,321 | +23% | 0% | $367,607 |
| Point72 Asset Management, L.P. | 0.25% | 18,296 | 0% | $330,975 | |
| FMR LLC | 0.24% | 17,156 | 0% | 0% | $310,352 |
| MORGAN STANLEY | 0.22% | 15,991 | -56% | 0% | $289,276 |
| CITADEL ADVISORS LLC | 0.22% | 15,577 | 0% | $281,788 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.19% | 14,018 | 0% | $253,586 | |
| JANE STREET GROUP, LLC | 0.19% | 13,990 | -37% | 0% | $253,080 |
| NORTHERN TRUST CORP | 0.17% | 12,340 | +12% | 0% | $223,231 |
| Walleye Capital LLC | 0.17% | 12,169 | 0% | $220,137 | |
| Connor, Clark & Lunn Investment Management Ltd. | 0.14% | 10,446 | 0% | $188,968 | |
| BANK OF AMERICA CORP /DE/ | 0.14% | 10,387 | +78% | 0% | $187,901 |
Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 354,607 | $1,677,293 | -$380,660 | $4.73 | 7 |
| 2025 Q4 | 2,049,655 | $37,062,796 | +$3,113,209 | $18.09 | 40 |
| 2025 Q3 | 1,883,136 | $26,983,314 | +$1,944,887 | $14.33 | 36 |
| 2025 Q2 | 1,803,350 | $13,921,685 | -$1,938,164 | $7.72 | 32 |
| 2025 Q1 | 2,086,793 | $12,393,904 | -$4,023,428 | $5.94 | 36 |
| 2024 Q4 | 2,368,286 | $31,519,295 | -$410,987 | $13.31 | 41 |
| 2024 Q3 | 2,414,500 | $19,628,975 | -$1,762,796 | $8.13 | 33 |
| 2024 Q2 | 2,653,675 | $22,554,322 | +$22,225,788 | $8.50 | 43 |